Research
Hormonal
A single administration of senolytic CAR T cells targeting uPAR eliminates senescent cells in aged mice, resulting in improved glucose tolerance, reduced fasting glucose, and enhanced exercise capacity.
This research suggests that targeting senescent cells via a single cellular therapy can reverse age-related metabolic decline and improve physical fitness in mice. While not yet available for human use, it highlights senolytics as a potential future intervention for longevity.
GoodSupportsHIGH confidence
Treatment with anti-uPAR CAR T cells improves exercise capacity in physiological aging, and it ameliorates metabolic dysfunction (for example, improving glucose tolerance) in aged mice and in mice on a high-fat diet. Importantly, a single administration of these senolytic CAR T cells is sufficient to achieve long-term therapeutic and preventive effects.
Why this rating
High-quality controlled animal study with multiple independent experiments, though not yet in humans.
Source
Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction
Corina Amor et al. · Nature Aging · 2024
DOI 10.1038/s43587-023-00560-5
mechanism_onlyCited 177×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Prophylactic administration of uPAR-targeting CAR T cells in young mice prevents the development of age-related metabolic dysfunction and maintains exercise capacity into old age.Good
- uPAR-targeting CAR T cells effectively treat metabolic syndrome induced by a high-fat diet in young mice, improving body weight, glucose tolerance, and insulin sensitivity.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →